The global cetuximab market size was valued at USD 1.13 billion in 2024 and is expected to reach USD 1.85 billion by 2032, at a CAGR of 6.36% during the forecast period
The market growth is largely fueled by the increasing prevalence of colorectal and head & neck cancers, for which cetuximab has been a critical targeted therapy. Expanding indications and advancements in monoclonal antibody technology are further strengthening its clinical utility and market demand
Furthermore, the rising geriatric population, increasing awareness about early cancer diagnosis, and growing investment in oncology research are positioning cetuximab as a valuable therapeutic option. These converging factors are accelerating its adoption across global healthcare systems, thereby significantly boosting the industry's growth
